Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
57,056,058
-
Total 13F shares
-
7,212,783
-
Share change
-
+7,212,667
-
Total reported value
-
$63,765,000
-
Put/Call ratio
-
203%
-
Price per share
-
$8.84
-
Number of holders
-
32
-
Value change
-
+$63,764,000
-
Number of buys
-
31
Institutional Holders of Astria Therapeutics, Inc. - Common Stock, $0.001 par value per share (ATXS) as of Q3 2021
As of 30 Sep 2021,
Astria Therapeutics, Inc. - Common Stock, $0.001 par value per share (ATXS) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,212,783 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Fairmount Funds Management LLC, VANGUARD GROUP INC, Cormorant Asset Management, LP, VR Adviser, LLC, CITADEL ADVISORS LLC, COMMODORE CAPITAL LP, Alyeska Investment Group, L.P., and Soleus Capital Management, L.P..
This page lists
32
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.